While there are currently no PPARδ agonists in clinical use, promising studies in animals have demonstrated that activating PPARδ has beneficial effects on obesity, hypercholesterolemia, insulin resistance, and exercise endurance (20, 21). This evidence concerns the gene PPARD and familial hypercholesterolemia.